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Pharmacogenetics primarily uses genetic variation to identify subgroups of patients who may respond differently
to a certain medication. Since its first description, the field of pharmacogenetics has expanded to study a broad
range of cardiovascular drugs and has become a mainstream research discipline. Three principle classes of
pharmacogenetic markers have emerged: 1) pharmacokinetic; 2) pharmacodynamic; and 3) underlying disease
mechanism. In the realm of cardiovascular pharmacogenetics, significant advances have identified markers in
each class for a variety of therapeutics, some with a potential for improving patient outcomes. While ongoing
clinical trials will determine if routine use of pharmacogenetic testing may be beneficial, the data today support
pharmacogenetic testing for certain variants on an individualized, case-by-case basis. Our primary goal is to re-
view the association data for the major pharmacogenetic variants associated with commonly used cardiovascu-
lar medications: antiplatelet agents, warfarin, statins, beta-blockers, diuretics, and antiarrhythmic drugs. In addi-
tion, we highlight which variants and in which contexts pharmacogenetic testing can be implemented by
practicing clinicians. The pace of genetic discovery has outstripped the generation of the evidence justifying its
clinical adoption. Until the evidentiary gaps are filled, however, clinicians may choose to target therapeutics to
individual patients whose genetic background indicates that they stand to benefit the most from pharmaco-
genetic testing. (J Am Coll Cardiol 2012;60:9–20) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.067“The right dose of the right drug to the right person” is
one of the goals of pharmacogenomics and personalized
medicine. The need for pharmacogenomics in clinical prac-
tice is underscored, for example, by the improved ischemic
outcomes with newer platelet P2RY12 receptor inhibitors
which also have higher risk of adverse events compared to
clopidogrel (1,2). Therefore, there is a critical need to target
therapeutics to individual patients who stand to benefit the
most and suffer the least.
Principles of Pharmacogenetics
A prerequisite for pharmacogenetics is heterogeneity in drug
response. The definitions of drug response are varied and can
include surrogate measurements measured in the laboratory
(e.g., international normalized ratio [INR] for warfarin) or
clinical endpoints (e.g., stent thrombosis for clopidogrel).
A genetic basis for drug response is suggested when
responses are similar within family members (and therefore
are heritable) or significantly different in across ethnic
backgrounds. Underlying genetic variation can be deter-
mined either using a targeted approach where known
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accepted January 18, 2012.variants in candidate genes are hypothesized to influence
drug response or genome-wide association—an “unbiased”
screen for common variants across the entire genome. Rare
genetic variants missed by genome-wide association studies
(GWAS) can be identified through sequencing candidate
genes, exomes, or the entire genome in the case of rare
drug-induced adverse events.
Three broad classes of genetic variants influence drug
response: 1) pharmacokinetic; 2) pharmacodynamic; and
3) those associated with the underlying disease mechanism
(Table 1, Fig. 1). This review will discuss specific drugs, and
in each case, we will apply these pharmacogenetic principles
followed by potential clinical implications.
Statins
Statins (3-hydroxy-3methylglutaryl-coenzyme A reduc-
tase [HMGCR] inhibitors) can elicit 4 types (at least) of
“responses”: 1) low-density lipoprotein cholesterol (LDLc)
lowering; 2) protection from cardiovascular events; 3) mus-
culoskeletal side effects; and 4) statin adherence.
LDLc lowering. The majority of patients respond with
30% to 50% LDLc reduction; however, there is wide (10%
to 70%) variation (3). Two loci appear to affect LDLc
lowering: HMGCR and APOE (Table 2).
HMGCR. Carriers of a minor haplotype (defined by 3
single nucleotide polymorphisms [SNPs]: rs17244841,
rs17238540, and rs3846662) of HMGCR experience a 5%
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with pravastatin (4) or simvasta-
tin (5) due to an alternatively
spliced HMGCR transcript that
produces a version of HMGCR
that is less sensitive to simvasta-
tin inhibition (6). This haplotype
was not identified in a GWAS
with atorvastatin (7), and there-
fore, whether this association
holds for other statins is unclear.
APOE. Two variants, rs7412
and rs429358, define 3 haplotypes,
namely, 2, 3, and 4, that are
associated with lipid, cognitive,
and thrombotic traits. In general,
the magnitude of LDLc lowering
is greatest for carriers of 2, fol-
lowed by 3, and 4 haplotypes,
respectively. The influence of
APOE haplotypes appears to be
consistent across variety of statin
ypes (4,7,8) and doses (8), and results in mild (15%)
ttenuations of LDLc lowering.
dditional loci. Information on ABCB1 and ABCG2 can
e found in the Online Appendix.
eduction in cardiovascular events. Statins prevent car-
iovascular disease by lowering LDLc and potential pleio-
ropic effects. There are few genetic predictors of these
leiotropic benefits, but the rs20455 polymorphism in
inesin-like protein 6 (KIF6, an underlying disease gene)
ay be a candidate. Carriers of the risk allele may receive a
reater benefit from statin therapy compared to noncarriers
espite equal LDLc, triglycerides, or C-reactive protein
eduction (9,10). However, subsequent genome-wide meta-
nalysis of large randomized placebo-controlled statin trials
ound no evidence for association with coronary artery
isease (11) or any differential treatment benefit with statin
herapy (12,13).
tatin-induced musculoskeletal side effects. Statins have
well-defined safety profile, but come with a small risk of
usculoskeletal side effects (14). Genetic variants in the
epatic transporter, SLCO1B1, influence the risk of adverse
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
BP  blood pressure
CYP  cytochrome P450
GWAS  genome-wide
association study
HR  heart rate
INR  international
normalized ratio
LDLc  low-density
lipoprotein cholesterol
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RF  reduced function
SNP  single nucleotide
polymorphism
Sources of Pharmacogenetic VariationTable 1 Sources of Pharmacogenetic Variation
Category Description
Pharmacokinetic Variability in concentration of drug at site of
drug effect
Pharmacodynamic Variability in drug ability to influence its targe
Underlying disease mechanisms Variability in disease being treatedvents (Table 2); it does not appear that cytochrome P450
CYP) SNPs influence statin-induced side effects.
LCO1B1. The solute carrier organic anion transporter
family, member 1B1 gene (SLCO1B1, also referred to as
SLC21A6, OATP-C, or OATP1B1) harbors many genetic
variants, and each variant is numerically and sequentially
labeled beginning with the unmutated copy of the gene, *1
(referred to as “star 1”) followed by *2, *3, *4, and so forth.
The *5 variant (rs4149056, Val174Ala) interferes with the
localization of this transporter to the hepatocyte plasma
membrane (15) and leads to higher plasma statin concen-
trations (16–18). In candidate gene and GWAS, carriers of
*5 are at 4- to 5-fold increased risk of severe, creatine kinase
(CK)- positive simvastatin-induced myopathy and 2- to
3-fold increased risk of CK- negative myopathy (19,20).
In trials of randomly assigned statins as well as in
observational studies, the risk for myopathy with *5 depends
on the statin type: the risk is greatest for simvastatin 
atorvastatin  pravastatin, rosuvastatin, or fluvastatin (20–23).
These effects parallel the influence of the *5 allele on the
clearance of these statins (16–18,24) and thus appear to be
statin-specific.
Adherence to statin therapy. Often, statin therapy is
hampered by nonadherence. Although the genetics of ad-
herence to statins has not been studied in any great depth,
2 studies (a clinical trial and observational cohort) observed
that carriers of the SLCO1B1*5 allele have a higher rate of
statin nonadherence (20,25).
Clinical implications for statin pharmacogenetics. It is
unlikely that genetic testing for statin efficacy will enter
clinical care since the magnitude of associations is small
(10% to 15% differences in LDLc lowering), and
physicians can reasonably forecast the magnitude of
LDLc lowering based on statin type, dose, and baseline
LDLc.
In contrast, statin-induced side effects and nonadherence
are less predictable. While the current level of evidence
surrounding SLCO1B1*5 may not support prospective
genotyping at this time, the test is currently offered on
consumer-directed whole genome genotyping platforms
(e.g., 23andMe, deCODEME, and so on). A potential strat-
egy for prospective SLCO1B1*5 testing might offer carriers
either pravastatin or rosuvastatin or fluvastatin as first-line
Types of Genes Examples
Drug-metabolizing enzymes
Drug transporters
Warfarin: CYP2C9
Clopidogrel: CYP2C19
Simvastatin: SLCO1B1
Metoprolol: CYP2D6
Transmembrane receptors
Intracellular enzymes
Clopidogrel: P2RY12
Simvastatin: HMGCR
Metoprolol: ADBR1
Often downstream or independent of drug target Hydrochlorothiazide: ADD1tSimvastatin: APOE
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clearance.
Thienopyridines
Thienopyridines are effective in patients with acute coronary
syndrome (ACS) and percutaneous coronary intervention
(PCI); however, some patients remain at risk for death,
myocardial infarction (MI), and stent thrombosis. Platelet
function in response to clopidogrel is variable (26), heritable
(27), and reduced inhibition predicts future events (28);
therefore, clopidogrel is a prime candidate for pharmacoge-
netics. Clopidogrel pharmacogenetics centers around 2 loci,
CYP2C19 (pharmacokinetic) and ABCB1 (pharmacoki-
etic); other loci, CYP2C9 (pharmacokinetic), PON1
pharmacokinetic), and P2RY12 (pharmacodynamic) may
lso influence response (Table 3).
latelet function in response to clopidogrel. CYP2C19.
lopidogrel is an inactive prodrug activated by several
nzymes, including CYP2C19, to an active metabolite that
nhibits the platelet adenosine diphosphate receptor,
2RY12 (29). CYP2C19 *2 (rs4244285) is the most com-
on reduced-function (RF) variant; additional, rare variants
imic the *2 allele: *3 [rs4986893], *4 [rs28399504], *5
rs56337013]) (30). An individual person’s genotype can
e characterized in 3 ways: 1) presence of at least 1 RF
llele (carrier vs. noncarrier); 2) the number of RF alleles
i.e., 0, 1, 2); or 3) the predicted, total CYP2C19 enzymatic
ctivity (Table 4). Carriers of *2—also referred to as
Figure 1 Categories of Major Cardiovascular Pharmacogenetic
Genetic variants that influence the response to cardiovascular agents fall into 3 b
3) underlying disease mechanism.ntermediate metabolizers or poor metabolizers—produceower active metabolite and have attenuated platelet inhibi-
ion (31). In general, there is a gene-dose effect where
ncreasing number of RF alleles (i.e., 0, 1, 2, or extensive
etabolizers, intermediate metabolizers, and poor metabo-
izers) predicts a decreasing amount of platelet inhibition
27,31,32). Carriers of another variant *17 (rs3758581,
ltrametabolizers) exhibit increased CYP2C19 activity, pro-
uce more active metabolite, and improved platelet inhibi-
ion, in most reports (33,34).
Higher loading and maintenance doses (e.g., 1,200 mg
nd 150 mg/day) appear, in part, to overcome the effects
f the *2 allele (30,32,35,36), although not completely
37), and can require up to 300 mg/day (38). Ticlopidine
39), prasugrel (31,40,41), and ticagrelor (42) all produce
niform platelet inhibition in *2 carriers and noncarriers.
BCB1. The adenosine triphosphate-binding cassette, sub-
family B (MDR/TAP), member 1 (ABCB1) gene encodes
an apical membrane protein in enterocytes and hepatocytes
and serves to reduce bioavailability. Clopidogrel appears to be
handled by this transporter, and 3 SNPs—C1236T (rs1128503),
G2677T (rs2032582), and C3435T (rs1045642)—capture the
common genetic variation at this locus. Persons who carry a
T allele at each SNPs (i.e., the T-T-T haplotype) produced
reduced active metabolite (43) in an initial report. Despite
this initial observation, the link to reduced platelet inhibi-
tion has been difficult to establish (27,30), although may be
present for persons who carry 2 copies of the T-T-T
nts
ategories: 1) pharmacokinetic; 2) pharmacodynamic; andVaria
road chaplotype (44). As with CYP2C19 variants, prasugrel-
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Clinical Cardiovascular Pharmacogenetics July 3, 2012:9–20induced platelet inhibition is not affected by T-T-T haplo-
type (44).
Additional loci. Using GWAS, investigators have unsuc-
cessfully searched for additional variants for clopidogrel
(27). An additional discussion of genetic variation at
ABCB1, P2RY12, CYP2C9, and PON1 can be found in the
Online Appendix.
Clinical response to clopidogrel. CYP2C19. In parallel
with the platelet function data, the CYP2C19*2 allele is
associated with a graded risk of death, MI, or stroke.
Carriers of 1 allele (intermediate metabolizers) have a
1.5-fold increased risk, and carriers of 2 alleles (poor
metabolizers) experience a 1.8-fold increase. This pattern
also extends to stent thrombosis as well with a 2.6- and
4-fold increased risk in those with 1 and 2 *2 alleles,
respectively (32,45–49). Therefore, the CYP2C19 genetic
ssociations with platelet function are mirrored in the
linical response to clopidogrel in the setting of PCI. These
bservations formed the foundation for updating the clopi-
ogrel label by the Food and Drug Administration to
nclude pharmacogenetic information. Similarly, the gain of
unction variant, CYP2C19*17, is associated with increased
isk of bleeding (50), and protection from ischemic events
51) CYP2C19*2 carriers treated with prasugrel or ticagrelor
o not show a heightened risk of cardiovascular death, MI,
troke, or stent thrombosis (40,52).
BCB1. Carriers of 2 copies of the ABCB1 T-T-T haplo-
type treated with clopidogrel are at an increased risk for
subsequent death, MI, or stroke compared to persons who
carried none, thus mirroring the platelet function data
(44,45,52). Genetic variation at the ABCB1 locus does not
appear to influence prasugrel- or ticagrelor-treated patients
(40,52).
Clinical implications. The current state of evidence reflects
a strong and consistent association with the CYP2C19*2 allele
and an increased risk for cardiovascular outcomes in ACS/
PCI patients treated with clopidogrel, although not other
settings (51). Alternative antiplatelet agents (i.e., prasugrel
and ticagrelor) mitigate the adverse risk of CYP2C19*2-
associated adverse events. Although CYP2C19 genotyping is
commercially available, whether genotype-guided therapy
will improve outcomes or reduce costs is unknown. Con-
sensus statements (53) currently do not recommend routine
testing. However, there is sufficient evidence to support
physicians who may choose to pursue CYP2C19*2 testing in
selected patients: 1) for diagnosis in patients with compli-
cations of clopidogrel therapy such as stent thrombosis in
compliant clopidogrel users; or 2) for the choice of dual
antiplatelet therapy in the ACS/PCI setting where the
physician believes that additional information regarding
the risk/benefit profile for clopidogrel will influence the
choice of drug therapy (54). Outside of these scenarios,
the ACS/PCI setting, or situations where there are ample
data to guide drug choice (e.g., ST-segment elevation MI
[55], diabetic patients [56], age 75 years, or priorM
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July 3, 2012:9–20 Clinical Cardiovascular Pharmacogeneticstransient ischemic attack/stroke), there is minimal ratio-
nale to support CYP2C19 testing.
Based on the available data, it is reasonable that if a
erson is found to be a poor metabolizer (Table 4), then an
lternative to clopidogrel, such as prasugrel or ticagrelor,
hould be considered. This seems preferable over increased
lopidogrel doses, which have not shown benefit over
tandard dose clopidogrel (57–59). The greatest uncertainty
s in the intermediate metabolizer group (i.e., those with 1
oss of function allele) and is where integration of other
linical risk factors such as diabetes, body mass index, cost,
nd other bleeding and thrombosis risk factors need to be
onsidered in determining the therapy with the optimal
isk:benefit profile.
spirin
spirin irreversibly inhibits prostaglandin G/H synthase 1
PTGS1, or COX-1) and the conversion of arachidonic acid
o thromboxane. With adequate dosing and compliance,
spirin is capable of completely inhibiting COX-1 in 99%
f persons; thus, true “aspirin resistance” is rare (60).
owever, alternate agonists such as adenosine diphosphate
nd collagen can produce robust aggregation in the face of
omplete COX-1 inhibition (61), a response that demon-
trates wide interindividual variability (62), heritability
63,64), and at high levels, association with future cardio-
ascular events (65,66), therefore making aspirin a candidate
or pharmacogenetic discovery. Because aspirin uniformly
Main Genetic Associations With the Response to ClopidogrelTable 3 Main Genetic Associations With the Response to Clop
Gene Variant(s)
Risk Allele/
Haplotype Frequencies
Drug RCaucasians Africans Asians
CYP2C19 *2 (rs4244285) 16% 14% 27% Drug conc
recurre
GWAS
CYP2C19 *17 (rs3758581) 5% 10% 6% Drug conc
bleedin
ABCB1 T-T-T haplotype defined by
T allele at C1236T
(rs1128503), G2677T
(rs2032582), and
C3435T (rs1045642)
71% 12% 65% Drug conc
recurre
MI  myocardial infarction; DMET  drug metabolizing enzyme and transporter panel; other abbr
CYP2C19 Diplotype Classification*Table 4 CYP2C19 Diplotype Classification*
Alleles Classification
*1 and *1 Extensive metabolizer
*2/*3/*4/*5/*6 and *1/*17 Intermediate metabolizer
*2/*3/*4/*5/*6 and *2/*3/*4/*5/*6 Poor metabolizer
*1/*17 or *17/*17 Ultrametabolizera*Adapted from Ingelman-Sundberg et al. (147) and Scott et al. (148).nhibits its target, COX-1, there are no pharmacokinetic or
harmacodynamic genetic considerations. Instead, investi-
ators have focused on platelet function loci (underlying
isease) and LPA (underlying disease).
Variants in several platelet genes, namely, PEAR1,
ITGB3, VAV3, GPVI, F2R, and GP1BA, are associated with
latelet function in response to aspirin (67–70). One with
oderate evidence is rs5918 in ITGB3 where carriers of the
isk allele have heightened platelet function on aspirin
71–73). Recent GWAS of platelet function in response to
spirin have identified additional genetic loci that have yet
o be replicated (74). Finally, the most robust association
omes from a large study that found carriers of the minor
llele for an intronic SNP, rs12041331, in PEAR1 have
igher PEAR1 platelet protein content and heightened
latelet function in response to aspirin (75).
The link to an increased risk of clinical events in aspirin
sers has not been established despite several large studies
76,77), although the PEAR1 variant rs12041331 has not
et been tested. An uncommon variant in LPA (rs3798220)
eems to modify the protective effects of aspirin: carriers
ad a more than 2-fold reduction in the risk for cardio-
ascular disease with aspirin, whereas noncarriers (95%
f Caucasians) had none in a large placebo-controlled
linical trial (78).
linical implications. Because of the lack of consistent or
reliminary associations with the variants described in the
receding text, there is currently no role for genetic testing
or aspirin.
arfarin
hree loci contribute to the heterogeneity in response:
YP2C9 (pharmacokinetic), VKORC1 (pharmacodynamic),
nd CYP4F2 (pharmacodynamic) (Table 5).
arfarin dose requirements. CYP2C9. CYP2C9 is re-
ponsible for S-warfarin (the more active enantiomer) clear-
el
se/Type of Study
Effect of Variant
With Risk Allele Ref. #
ion, platelet function,
stent thrombosis/
, CG
2Active metabolite concentration
2Inhibition of platelet function
1Risk of recurrent MI, stroke,
stent thrombosis
Graded risk with 0, 1, or 2 alleles
31,32,45–47,52
ion, platelet function, 1Active metabolite concentration
1Inhibition of platelet function
1Risk bleeding
32,33,50
ion, platelet function,
stroke, death/CG
2Active metabolite concentration
2No change in inhibition of
platelet function
1Risk of recurrent MI, stroke,
death (in carriers of 2 T-T-T
haplotypes)
27,30,43,45,48,49,52
ns as in Table 2.idogr
espon
entrat
nt MI,
, DMET
entrat
g/CG
entrat
nt MI,nce. The 2 most common reduced-function variants are
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Clinical Cardiovascular Pharmacogenetics July 3, 2012:9–20*2 (rs1799853) and *3 (rs1057910). The CYP2C9*2 allele
reduces warfarin clearance by 30% and the *3 allele by
90% (79), which translate into 19% and 33% reductions
per allele in warfarin dose requirements compared to
noncarriers (80).
VKORC1. Vitamin K epoxide reductase complex, subunit 1
(VKORC1) is warfarin’s target (81,82), and resequencing
this gene identified 2 haplotypes (A and B defined by the
alleles at 5 SNPS: rs7196161, rs9923231, rs9934438,
rs8050894, and rs2359612) that influence VKORC1 gene
xpression and predict warfarin dose requirements (83). Of
hese 5 SNPs, an A allele at rs9923231 (also referred to as
1639 GA and the 3673 SNP) in the promoter region is
esponsible for reducing: VKORC1 gene expression (84).
Therefore, carriers of an A allele at rs9923231 (or the A
haplotype) require a 30% per allele reduction in warfarin
dose requirements (85).
CYP4F2. Several GWAS have not only confirmed the
observations above but also have identified a novel associa-
tion between rs2108622 in CYP4F2 and reduced hepatic
YP4F2, higher levels of hepatic vitamin K, and higher
arfarin dose requirements (86–90).
dditional loci. Additional information regarding CALU
nd GGCX can be found in the Online Appendix.
linical response to warfarin. RETROSPECTIVE STUDIES.
Standard dosing algorithms (i.e., a 5 mg or 10 mg loading
dose followed by titration based on the INR) lead to an
increased risk of an out-of-range INR (4.0) or a delay in
the time-to-therapeutic range INR in carriers of the
CYP2C9*2 or CYP2C9*3 alleles (91,92), the A haplotype or
allele of the1639 SNP in VKORC1 (93), or the T allele
in CYP4F2 (94). Importantly, only variants in CYP2C9 have
been linked to the risk of bleeding (91,92).
PROSPECTIVE STUDIES OF TAILORED WARFARIN THERAPY.
Small randomized pilot studies, parallel cohort studies, and
single arm studies with or without historical controls have
prospectively explored genetically guided warfarin therapy.
Main Genetic Associations With the Response to WarfarinTable 5 Main Genetic Associations With the Response to Warf
Gene Variant(s)
Risk Allele Frequencies
Caucasians Africans Asians
CYP2C9 *2 (rs1799853)
*3 (rs1057910)
*2: 10%
*3: 6%
1%
1%
1%
4%
Dr
VKORC1 1639 (rs9923231)* 60% 98% 2% Wa
CYP4F2 rs2108622 23% 6% 25% Wa
*Carriers of the risk, A, allele are also carriers of the A haplotype.
INR  international normalized ratio; other abbreviations as in Tables 2 and 3.Whereas some studies suggest a benefit over standard itherapy (95–97), others failed to show any significant
advantage (98) except for smaller and fewer dosing changes
and INR measurements (99). Definitive clinical trials are
ongoing to assess the benefit of incorporating genetics into
warfarin therapy.
Clinical implications. There are strong genetic associa-
tions surrounding CYP2C9, VKORC1, and CYP4F2 variants
hat influence the response to warfarin. Commercial testing
nd algorithms that assist in the interpretation of genotypes
re available. Therefore, there is evidence to justify and tools
o enable genotype-guided warfarin therapy. Until large
cale trials demonstrate a benefit for routine testing, physi-
ians may choose to pursue testing in selected patients who
hey feel may benefit by: 1) diagnosing those with compli-
ations from warfarin therapy (e.g., hemorrhage); 2) pre-
icting dose for those at high risk of bleeding (e.g.,
triple-therapy” with aspirin, clopidogrel, and warfarin); or
) weighing the costs of newer anticoagulants against
arfarin.
iuretics
lood pressure–lowering response. The adducin 1 (alpha)
ene (ADD1, underlying disease) is implicated in animal
nd human sodium handling (100), and persons with a
ly460Trp substitution are more salt sensitive and have
nhanced blood pressure (BP) lowering with thiazide di-
retics (100).
linical outcomes. In an observational study, patients
ith Trp460 who were treated with thiazide diuretics
xperienced a greater protection from MI and stroke than
atients with Gly460 (101). However, this difference in the
rotective effects of diuretics could not be replicated in
everal larger studies (102–104).
linical implications. Given the inconsistent associations
nd lack of a commercially available test, the use of this
enetic variant in guiding treatment options in hypertension
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Beta-adrenergic receptor antagonists (or beta-blockers) are
a diverse class of agents that primarily antagonize the beta-1
adrenergic receptor, encoded by ADBR1. Accordingly,
changes in heart rate (HR), BP, and left ventricular ejection
fraction (LVEF) are considered the surrogate responses in
place of clinical responses such as protection from MI,
death, or heart failure. Variation in CYP2D6 (pharmacoki-
netic) and ADRB1, ADRB2, and GRK5 (all pharmacody-
namic) have received the most attention (Table 6).
Heart rate and blood pressure reduction. CYP2D6. Beta-
blockers are substrates for CYP, and metoprolol is exten-
sively metabolized by hepatic CYP2D6. The most common
RF variant CYP2D6*4 (rs3892097) results in the absence of
CYP2D6 activity. Carriers have a higher systemic exposure
to metoprolol (105), which translates into a greater reduc-
tion in HR and BP (106,107). Beta-blockers such as
atenolol and carvedilol (108) do not require CYP2D6 for
heir metabolism.
DRB1. Ethnic differences in the dose response for pro-
pranolol (109) motivated pharmacodynamic genetic inves-
tigations of beta-blockers. Two variants in ADBR1, the
Ser49Gly (rs1801252) and Arg389Gly (rs1801253), lead to
impaired down-regulation (110) and higher signal transduc-
tion, respectively (111). Therefore, carriers of either variant
have enhanced, beta-1-receptor activity and more beta-
blocker sensitivity. Healthy volunteers and patients with
hypertension who carry 2 Arg389 variants have a greater
HR (112) or BP (113) reduction mainly with metoprolol,
lthough not with all beta-blockers (114).
In patients with systolic heart failure treated with either
etoprolol or carvedilol (115), but not bucindolol (116),
arriers of 2 copies of the ADBR1 Arg389 variant had
ignificantly greater improvements in LVEF compared to
he Gly389 carriers.
DRB2. Genetic variation in the beta-2 adrenergic receptor
(ADBR2) centers around 2 variants: Arg16Gly (rs1042713) and
lu27Gln (rs1042714). Receptors with Gly16 versus Arg16
ave enhanced down-regulation of ADBR2. In contrast,
eceptors with Glu27 appear to be resistant to down-
egulation (117). Extension to variation in BP or HR
owering in response to beta-blocker therapy has not been
emonstrated (114).
RK5. Downstream of the beta-1-adrenergic receptor are
G-protein coupled receptor kinases responsible for desensi-
tization of the beta-1-adrenergic receptor. A Glu41Leu
genetic variant in 1 of these kinases, G protein-coupled
receptor kinase 5 (GRK5), is more prevalent in African
Americans. The Leu41 more effectively uncoupled
isoproterenol-stimulated responses than GRK5-Q41, thus
producing a pharmacological-like “beta-blockade” in mice
(118), although with no differences in atenolol-induced HR
reduction in humans (119). M
a T C A A
B
P

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ADRB1. In heart failure patients, when compared to pla-
cebo, ADRB1 Arg389 homozygotes had a greater reduction
in the time to first hospitalization or death when treated
with bucindolol (116) but not carvedilol or metoprolol
(120–125) compared to Gly389 carriers. Whether these
differences are due to drug specific effects (i.e., bucindolol vs.
metoprolol) or the play of chance has not been adequately
tested. In patients with chronic coronary artery disease
randomly assigned to verapamil or atenolol, carriers of at
least 1 copy of the Ser49/ Arg389 haplotype had a 9- versus
2-fold worsened prognosis when assigned to verapamil
versus atenolol (126) despite equivalent BP and HR control
in both groups.
ADRB2. One study examined the influence of genetic
variation at ADRB2 and its influence on ACS patients and
found those homozygous for both the Arg16 and Glu27
alleles had a 20% rate of subsequent death versus 6% of
those homozygous for both Gly16 and Gln27 (125). This
trend has been observed in some studies of patients with
heart failure (124), although not all (122,123,126).
GRK5. Extension of the associations of the Glu41Leu
variant to clinical outcomes of patients was demonstrated in
1 study where Leu41 carriers exhibited improvement in sur-
vival compared to Glu41 carriers (118), although not in
another, larger study (121).
Adverse events. Metoprolol-induced adverse events (e.g.,
bradycardia) are associated with CYP2D6*4 in 2 studies,
each numbering 1,000 treated patients (127,128), al-
though not in smaller studies (129,130).
Clinical implications. In general, carriers of the Arg389
variant have: 1) enhanced reduction in HR and BP; 2) larger
improvements in LVEF; and 3) longer survival when
treated with chronic beta-blocker therapy compared to
persons with the Gly389 variant. Although it is unlikely that
beta-blocker therapy will ever be withheld for carriers of the
Gly389 variant, a potential application of these findings
would be to consider advanced heart failure therapies (e.g.,
left ventricular assist devices, biventricular pacing, or trans-
plantation) at an earlier stage in patients with the Gly389
variant.
Because certain beta-blockers such as atenolol and carve-
dilol are minimally handled by CYP2D6 (131), these may be
reasonable alternates for carriers of CYP2D6*4 with
metoprolol-induced bradycardia. Commercial testing for
CYP2D6*4 is available (e.g., Labcorp).
Antiarrhythmic Drugs
Digoxin and calcium-channel blockers. Many antiar-
rhythmics are known ABCB1 (described in preceding text)
substrates including verapamil, diltiazem, and digoxin. Ge-
netic variation in ABCB1 is inconsistently associated with
altered pharmacokinetic profiles (132–134), and there are
no reports of different clinical outcomes.Procainamide. Procainamide is rapidly converted by acet-
ylation into N-acetylprocainamide (NAPA, an active me-
tabolite) by hepatic acetyltransferases (NAT2, primarily).
Variability in hepatic acetylation capacity has long been
observed (135), and “slow acetylators” produce less NAPA.
Common genetic variants that decrease NAT2 activity are
*5/rs1801280, *6/rs1799930, *7/rs1799931, and *14/
rs1801279 (136,137). Although efficacy does not appear to
be related to variation in its pharmacokinetics, the induction
of drug-induced lupus-associated autoantibodies (138,139),
but not symptomatic, drug-induced lupus (138,139) has
been linked to the slow acetylator status.
Propafenone. The hepatic hydroxylation by CYP2D6 of
propafenone into 5-hydroxypropafenone demonstrates wide
interindividual variability (140). Carriers of CYP2D6*4 (a
reduced function allele) have reduced propafenone clearance
compared to noncarriers (140–142).
Antiarrhythmic efficacy. At low doses of propafenone,
CYP2D6*4 carriers have greater reduction in exercise- or
isoproterenol-induced HR compared to noncarriers (143),
although not with higher doses or without the “stress” of
exercise/isoproterenol (140,142,143). Further, CYP2D6*4
carriers have enhanced suppression of atrial and ventricular
arrhythmias compared to noncarriers in some studies
(141,144), although not in all (140,142) Therefore, there are
insufficient data to make any conclusions regarding
CYP2D6 genotype and antiarrhythmic efficacy.
Toxicity. Central nervous system side effects with
propafenone, as well as excessive beta-blockade, are correlated
with a higher concentration of systemic propafenone and,
accordingly, the CYP2D6 genotype (140).
Clinical implications. Antiarrhythmic drug pharmacoge-
netics represents a mixed collection of associations that do
not sufficiently translate to consistent associations of mean-
ingful clinical outcomes. Therefore, there is currently no
role for pharmacogenetic testing in the clinical use of these
medications.
Future Directions
The data to date support many common variants that alter
the pharmacologic properties of cardiovascular agents.
Newer medications such as prasugrel, ticagrelor, and apxi-
ban as well as older medications such as enalapril, spirono-
lactone, and angiotensin-receptor blockers that have variable
clinical effects are also candidates for a pharmacogenetic approach.
Novel systems approaches may elucidate additional deter-
minants of drug response. Broad “omics” approaches have
several advantages over traditional genetics-based research,
for example, 1) responding to the environment, and 2)
elucidating how the activity of entire pathways, instead of
individual genes, influence drug response.
The field of pharmacogenomics would benefit from the
development of thresholds of evidence for testing and
coverage by insurance. With the expanding number and
complexity of “-omic” markers of drug response is an equally
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those that demonstrate clinical utility. It may be unrealistic
to wait (or to require) a prospective, events-driven random-
ized controlled trial of each drug-marker combination. Even
when such trials are conducted, the results may be made
obsolete by new observations and/or approval of new drugs.
Therefore, genetic substudies of clinical trials and registries
may become the highest levels of evidence for the potential
benefits of using pharmacogenetic testing. Such standards
are common in many fields of medicine where there is often
a lack of randomized clinical trial data. Observational
studies and comparative effectiveness research will lay the
foundation for broad-based recommendations and transla-
tion of pharmacogenetic observations into a clinical para-
digm of personalized medicine to improve health outcomes.
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